Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ST-001 |
| Synonyms | |
| Therapy Description |
ST-001 is a formulation of phospholipid nanoparticles containing Fenretinide, a synthetic retinoid derivative, which may improve intravenous delivery and plasma concentration of Fenretinide (J Clin Oncol, Vol 43 (Suppl 16): TPS7096). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ST-001 | ST 001|ST001 | ST-001 is a formulation of phospholipid nanoparticles containing Fenretinide, a synthetic retinoid derivative, which may improve intravenous delivery and plasma concentration of Fenretinide (J Clin Oncol, Vol 43 (Suppl 16): TPS7096). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06922539 | Phase I | ST-001 | ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | Recruiting | USA | 0 |